TriSalus Life Sciences, Inc. (TLSI) Stock Forecast & Price Target
Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 18, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering TriSalus Life Sciences, Inc. (TLSI), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For TriSalus Life Sciences, Inc., analysts forecast revenue rising from $44.76M in 2025 to $149.21M in 2030; the average estimate for 2030 earnings per share is $0.70; with published estimates ranging from $0.67 to $0.74; 4 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (USD)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
TriSalus Life Sciences, Inc. (TLSI) forecast — frequently asked questions
What is the analyst price target for TriSalus Life Sciences, Inc.?
Analysts covering TriSalus Life Sciences, Inc. (TLSI) have a consensus price target of $10.00, 334.8% above the current price of $2.30. Published targets range from $4.00 to $12.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for TriSalus Life Sciences, Inc.'s earnings?
The average analyst estimate for TriSalus Life Sciences, Inc. (TLSI) earnings per share in 2030 is 0.70, with individual estimates between 0.67 and 0.74.
How much revenue is TriSalus Life Sciences, Inc. expected to make?
Analysts forecast TriSalus Life Sciences, Inc. (TLSI) revenue of $149.21M in 2030, based on 2 published estimates.
How many analysts cover TLSI?
4 analysts contribute estimates for TriSalus Life Sciences, Inc. (TLSI). Thin coverage makes an average less reliable.
Analyst forecasts for other Medical - Devices stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.